Business and Finance

EpiPen controversy has a new twist: paying lower rebates to state Medicaid programs

Sponsored by TGaS Advisors

Presidential politicking adds momentum to the growing backlash, and not just for Mylan

Healthcare research firm calls out the alarmist predictions over PCSK9s and other new drugs

CROs are expanding their scope of services

Deal deepens Teva’s business in generics

Advent joins Thomas Lee Partners in ownership of the clinical, commercial outsourcer

GE Healthcare makes a key acquisition in cell culture production technology

Technology projects, M&A and reimbursement questions drive growth

The annual Operation Pangea nets a next crop of crooks; consumer groups raise awareness

A repeat of the +6.5% cost trend indicates that medical costs are still rising above inflation

Internationalization of drug wholesaling is a factor in the name change

Branded products are 92% US market in dollar value, says IMS Institute

Bloomberg BusinessWeek rakes over charitable copay programs

PhRMA-sponsored study outlines the economic effects of US-based operations

Deals with Amgen and Sanofi/Regeneron enhance new pricing policies for specialty drugs

Managed care organizations are adjusting rapidly to onslaught of specialty products

The SP channel continues to grow, with manufacturers looking for more control over access

Both clinical research and commercial analytics markets to be served by combination

More healthcare stakeholders line up against the industry

Better access to hospital systems is a goal; pharmaceutical business is fading

Double-digit growth (12.2%) for the second year running